Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy
Thomas Faunce,Evan Doran,Evan Doran,David Henry,David Henry,Peter Drahos,Andrew Searles,Andrew Searles,Brita Pekarsky,Brita Pekarsky,Warwick Neville +10 more
Reads0
Chats0
TLDR
The AUSFTA medicines provisions may represent animportant precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will also beof great interest to policy makers in other jurisdictions as mentioned in this paper.Abstract:
On 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the world-respected process of federal government reimbursement after expert cost-effectiveness evaluation, popularly known as the Pharmaceutical Benefits Scheme ('PBS'). It remains uncertain what sort of impacts – if any – the Australia-United States Free Trade Agreement ('AUSFTA') will have on PBS processes such as reference pricing and their important role in facilitating equitable and affordable access to essential medicines. This is now the field of inquiry for a major three year Australian Research Council ('ARC')-funded study bringing together a team of senior researchers in regulatory theory from the Australian National University and pharmacoeconomics from the University of Newcastle. The project proposes to monitor, assess and analyse the real and potential impacts of the AUSFTA in this area, providing Australian policy-makers with continuing expertise and options. To the extent that the AUSFTA medicines provisions may represent animportant precedent in a global strategy by industry oncost-effectiveness evaluation of pharmaceuticals, the study will also beof great interest to policy makers in other jurisdictions.read more
Citations
More filters
Journal ArticleDOI
Effects of reference pricing in pharmaceutical markets: a review.
TL;DR: A systematic and updated survey of original scientific studies on the effect of the introduction of reference pricing (RP) policies in Organisation for Economic Co-operation and Development (OECD) countries found that both therapeutic RP (TRP) and GRP have been associated with significant and consistent savings in the first years of application.
Journal ArticleDOI
Trade, investment and public health: compiling the evidence, assembling the arguments
TL;DR: A slew of new agreements that coincided with the establishment of the WTO also sought to liberalize trade in services, create new rules for agricultural trade, expand intellectual property rights protections, and ensure that government food, health, or environmental regulations would not pose an unnecessary barrier to trade.
Journal ArticleDOI
Privatization of health services in less developed countries: an empirical response to the proposals of the World Bank and Wharton School.
TL;DR: Although the impact of privatization has differed among the Latin American countries studied, expansion of private insurance often has generated additional co-payments, which have increased rather than decreased out-of-pocket expenditures, thereby worsening access to needed services.
Journal ArticleDOI
Moving Theory into Practice: Human Rights Impact Assessment of Intellectual Property Rights in Trade Agreements
Lisa Forman,Gillian MacNaughton +1 more
TL;DR: The work in this article explores the development of methodologies for human rights and right to health-specific impact assessment (RTHIA) of trade-related intellectual property rights of medicines in low and middle-income countries.
Journal ArticleDOI
Disease mongering: expanding the boundaries of treatable disease.
Evan Doran,David Henry +1 more
TL;DR: The term ‘disease mongering’ has been applied to the promotional activities of medical industries where companies have worked through partnerships, which have included clinicians, to expand the boundaries of treatable disorders.
References
More filters
Journal ArticleDOI
Welfare Effects of Global Patent Protection
TL;DR: In this article, the authors examined the welfare effects of extending patent protection from the country where invention takes place to another country that is only a consumer of invented products, and showed that, while the welfare of the inventing country certainly rises with the extension of patent protection, that of the other country probably falls, and may well fall by more than the increase in welfare.
ReportDOI
Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms
TL;DR: This article examined responses to the Japanese patent reforms of 1988 and found no evidence of an increase in either R&D spending or innovative output that could plausibly be attributed to patent reform.
Journal ArticleDOI
Patent Breadth, Patent Life, and the Pace of Technological Progress
TL;DR: In this article, the authors define the length of time until one of these happens as the effective patent life, and show how it depends on patent breadth, and distinguish lagging breadth, which protects against imitation, from leading breadth, that protects against new improved products.
Journal ArticleDOI
150 Years of Patent Protection
TL;DR: This paper examined three sets of explanations for variations in the strength of patent protection across sixty countries and a 150-year period and found that countries with democratic political institutions are consistently more likely to have patent protection appear to be determined by historical factors.
Journal ArticleDOI
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.
TL;DR: The intensive evaluation process used in the Australian Pharmaceutical Benefits Scheme allowed for identification and correction of pharmacoecomomic analysis problems, but the resources that are required may be beyond the capacity of many organizations.